FGF23 and osteomalacia: Of note, in 2022, the first case of tumor-induced osteomalacia, another challenging cancer-related humoral syndrome underlying FGF-23 (fibroblast growth factor) excess with renal phosphate wasting effects (which was typically described in mesenchymal tumors, not necessarily malign) [177,178], was described in a 77-year-old lady confirmed with a pancreatic NET [179].